Abstracts tagged "SLE and outcome measures"

Abstract Number: 1687 • 2018 ACR/ARHP Annual Meeting
Systemic Lupus Flares Based on BILAG and Sledai Rules Are Inconsistent, but May be Better Understood Using Visual Analogue Scales
Aikaterini Thanou¹, Anca Askanase², Cristina Arriens³, Teresa Aberle³, Stan Kamp³, Eliza Chakravarty³, Judith A. James⁴ and Joan T. Merrill³, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Columbia University, College of Physicians & Surgeons, New York, NY, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Evaluation of lupus flares is inconsistent using glossary-based definitions for grading (1). BILAG 2004 rates flares by new/worse organ scores. The SELENA-SLEDAI flare index…
Abstract Number: 1688 • 2018 ACR/ARHP Annual Meeting
Changes in Heart Rate Variability Reflect Clinical Improvement and Flare in Systemic Lupus Erythematosus
Aikaterini Thanou¹, Stavros Stavrakis², Stan Kamp³, Paul Kamp³, Teresa Aberle³, Cristina Arriens³, Eliza Chakravarty³, Judith A. James⁴ and Joan T. Merrill³, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Ok, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Decreased heart rate variability (HRV) reflects autonomic dysfunction and inflammatory dysregulation and has been observed in SLE. We examined associations of HRV with clinical…
Abstract Number: 1638 • 2017 ACR/ARHP Annual Meeting
High Genetic Risk Score Is Associated with Increased Organ Damage in SLE
Sarah Reid¹, Andrei Alexsson¹, Martina Frodlund², Johanna K Sandling¹, Elisabet Svenungsson³, Andreas Jönsen⁴, Christine Bengtsson⁵, Iva Gunnarsson³, Anders A. Bengtsson⁴, Solbritt Rantapaa-Dahlqvist⁵, Maija-Leena Eloranta¹, Ann-Christine Syvänen⁶, Christopher Sjöwall², Lars Rönnblom¹ and Dag Leonard¹, ¹Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ²Department of Clinical and Experimental Medicine, Linköping University, Sweden, Linköping, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁴Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ⁵Dept of Public Health and Clinical Medicine/Rheumatology, Umeå University, Sweden, Umeå, Sweden, ⁶Uppsala University, Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease with a complex genetic etiology. Over 80 risk genes for SLE have been identified and…
Abstract Number: 768 • 2015 ACR/ARHP Annual Meeting
The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Instrument Correlates Between Trained Clinical Investigators and Clinicians
Anca Askanase¹, Teja Kapoor², Cynthia Aranow³, Karen H. Costenbader⁴, Jennifer Grossman⁵, Diane L. Kamen⁶, S. Sam Lim⁷, Mimi Kim⁸, Paola Daly^9,10, Leslie M. Hanrahan¹¹ and Joan T. Merrill¹², ¹NYU School of Medicine, New York, NY, ²Columbia University, New York, NY, ³Feinstein Institute for Medical Research, Mahasset, NY, ⁴Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ⁵Rheumatology, UCLA, LA, CA, ⁶Medicine, Medical University of South Carolina, Charleston, SC, ⁷Emory University School of Medicine, Atlanta, GA, ⁸Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁹Lupus Foundation of America, Washington DC, DC, ¹⁰Lupus Foundation of America, Washington, DC, ¹¹Lupus Fnd of America, Washington, DC, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Current SLE disease activity measures, such as SLEDAI and BILAG, can be challenging to score and interpret, making them impractical for use in…
Abstract Number: 2514 • 2013 ACR/ARHP Annual Meeting
The Brief Index of Lupus Damage, a Patient-Reported Measure of Lupus Damage, Is Sensitive to Change
Patricia P. Katz¹, Laura Trupin², Stephanie Rush³ and Jinoos Yazdany², ¹Medicine, University of California San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: Extending lupus research outside of the clinical setting remains a challenge, in part due to the complexity of measuring disease damage. Previously, we…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].